Answers are grounded in this paper and cite their sources.
Diclofenac potassium 25mg (Cataflam®, Novartis New Zealand Limited) was reclassified from prescription medicine to pharmacist-only sale in New Zealand in 1992. This paper discusses methodological issues in postmarketing surveillance of Cataflam. Consenting user-purchasers were recruited from 175 (16% of) pharmacies in New Zealand over 4 months. Purchasers were mailed a questionnaire for completion seven days after purchase. Those considered “at risk” of adverse events were resurveyed 30 days after purchase. The 1240 purchasers recruited returned 990 valid questionnaires (80% response). Of these, 56% (557) were mailed the second questionnaire (86% response). Two pharmacy-based adjunct studies allowed some data validation.
No takes yet. Share an insight, caveat, or question.
Emmerton et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: